Eplivanserin (SR46349)
Drugoral administration
NCT Number: NCT00308503
The aim of the study is to confirm the efficacy of eplivanserin 5mg/day on sleep maintenance of patients with primary insomnia using night polysomnography recordings over a 6-week treatment period corresponding to a stabilization of improvement of sleep.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Sanofi-Aventis, Macquarie Park, New South Wales, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion will be based on the nocturnal polysomnography (NPSG) recordings performed at the sleep laboratory during the two screening nights.
Exclusion criteria
oral administration
oral administration
Time frame: week 6
Time frame: week 6
Time frame: week 6
Sanofi
Industry
Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: A 6 Week, Multicenter, Randomized, Double -Blind, Placebo-controlled Study
Acronym: EPOCH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04598672
Chronic Disease, Disease Attributes
Oslo, Norway
View Trial DetailsNCT04092894
Confusion, Delirium
Boston, Massachusetts, United States
View Trial DetailsNCT04560595
Anxiety, Anxiety Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT04986904
Dyssomnias, Family Caregivers
Pittsburgh, Pennsylvania, United States
View Trial Details